4//SEC Filing
MOORE JOHN R 4
Accession 0001562180-24-001227
CIK 0001710072other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 5:43 PM ET
Size
19.9 KB
Accession
0001562180-24-001227
Insider Transaction Report
Form 4
MOORE JOHN R
General Counsel
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-02-07−17,993→ 105,004 totalExercise: $1.93Exp: 2030-12-15→ Common Stock (17,993 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-08−3,813→ 101,191 totalExercise: $1.93Exp: 2030-12-15→ Common Stock (3,813 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-09−8,029→ 93,162 totalExercise: $1.93Exp: 2030-12-15→ Common Stock (8,029 underlying) - Exercise/Conversion
Common Stock
2024-02-07$1.93/sh+17,993$34,726→ 17,993 total - Sale
Common Stock
2024-02-07$20.00/sh−17,993$359,864→ 0 total - Sale
Common Stock
2024-02-08$20.01/sh−3,813$76,285→ 0 total - Exercise/Conversion
Common Stock
2024-02-08$1.93/sh+3,813$7,359→ 3,813 total - Exercise/Conversion
Common Stock
2024-02-09$1.93/sh+8,029$15,496→ 8,029 total - Sale
Common Stock
2024-02-09$20.01/sh−8,029$160,657→ 0 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 30, 2023.
- [F2]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.15, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date.
Documents
Issuer
Edgewise Therapeutics, Inc.
CIK 0001710072
Entity typeother
Related Parties
1- filerCIK 0001191702
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 5:43 PM ET
- Size
- 19.9 KB